Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Analytical Method Development: Data Integrity in Method Development – V 2.0

Posted on By

Analytical Method Development: Data Integrity in Method Development – V 2.0

SOP for Ensuring Data Integrity During Analytical Method Development Activities


Department Analytical Method Development
SOP No. SOP/AMD/037/2025
Supersedes SOP/AMD/037/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP outlines the principles and procedures required to ensure data integrity during analytical method development activities. It ensures that all data—whether electronic or paper-based—are accurate, complete, consistent, and secure throughout their lifecycle.

2. Scope

This SOP applies to all data generated during method development, including raw data, chromatograms, spectra, calculations, reports, electronic audit trails, and records associated with analytical instrumentation and software within the AMD department.

3. Responsibilities

  • Analytical Scientists: Generate, record, and review data in accordance with ALCOA+ principles and GMP requirements.
  • QA: Conducts periodic data integrity audits and reviews audit trails and logbooks.
  • IT: Ensures access controls, backup, and system security for computerized systems.
  • Head – AMD: Ensures enforcement of data integrity procedures and takes corrective actions for any breach.

4. Accountability

The Head of AMD is accountable for ensuring continuous enforcement of data integrity practices across all AMD activities and reporting any suspected data falsification or non-compliance to senior management.

See also  Analytical Method Development: Literature Review for Method Development - V 2.0

5. Procedure

5.1 Data Integrity Principles (ALCOA+)

  1. Ensure that all data meet the following criteria:
    • Attributable: Data must clearly identify the person generating it.
    • Legible: Records must be readable and permanent.
    • Contemporaneous: Recorded at the time of activity.
    • Original: First recorded observation or certified true copy.
    • Accurate: Free from errors, edited with justification if needed.
    • Complete, Consistent, Enduring, Available: ALCOA+ attributes

5.2 Electronic Data Handling

  1. Use validated software systems with 21 CFR Part 11 compliance (e.g., Empower, LabSolutions).
  2. Enable secure login with role-based access control.
  3. Ensure electronic records are backed up on secure servers as per SOP/IT/005/2025.
  4. Enable and retain audit trails without overwrite capability.
  5. Printouts or exported data must be linked to original raw data for traceability.

5.3 Paper-Based Record Management

  1. Entries must be made using indelible ink and signed with date/time.
  2. No overwriting or backdating is permitted. Corrections must include:
    • Strike-through single line
    • Initials, date, and reason for change
  3. All paper records must be stored in secure, access-controlled storage areas.

5.4 Data Review and Approval

  1. All data must be reviewed by a second analyst or reviewer before final reporting.
  2. Review includes:
    • Chromatograms/spectra match calculations
    • Audit trails reviewed and signed
    • Any data exclusion is justified and approved by QA
  3. Document review status in Annexure-1: Data Integrity Review Checklist.
See also  Analytical Method Development: Preparation of Method Development Protocol - V 2.0

5.5 Audit Trail Monitoring

  1. Audit trails of key systems (HPLC, GC, UV) shall be reviewed weekly or per method lifecycle.
  2. Events monitored include:
    • Deletion of data files
    • Changes to integration parameters
    • Modifications to user access
  3. Record observations in Annexure-2: Audit Trail Review Log.

5.6 Data Integrity Breach Handling

  1. Suspected data manipulation or falsification must be reported immediately to QA and Head – AMD.
  2. QA initiates deviation report and conducts root cause analysis.
  3. Corrective actions may include:
    • User retraining
    • Revocation of access
    • Revision of SOPs
  4. All incidents to be tracked using Annexure-3: Data Integrity Incident Register.

5.7 Training and Awareness

  1. All analysts and reviewers must undergo annual data integrity training.
  2. Training topics include ALCOA+, audit trail use, record keeping, and data falsification consequences.
  3. Document participation in Annexure-4: Data Integrity Training Log.

6. Abbreviations

  • AMD: Analytical Method Development
  • QA: Quality Assurance
  • ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available
  • SOP: Standard Operating Procedure

7. Documents

  1. Data Integrity Review Checklist – Annexure-1
  2. Audit Trail Review Log – Annexure-2
  3. Data Integrity Incident Register – Annexure-3
  4. Data Integrity Training Log – Annexure-4
See also  Analytical Method Development: System Suitability Testing Parameters Design - V 2.0

8. References

  • FDA Guidance on Data Integrity and Compliance with CGMP
  • MHRA GxP Data Integrity Guidance
  • WHO TRS 1019 Annex 5 – Good Data and Record Management Practices
  • 21 CFR Part 11 – Electronic Records; Electronic Signatures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Data Integrity Review Checklist

Parameter Status Reviewed By Date
Data Attributability Verified Yes Rajesh Kumar 05/05/2025
Electronic Audit Trail Reviewed Yes Sunita Reddy 06/05/2025

Annexure-2: Audit Trail Review Log

Date System Activity Reviewer Observations
07/05/2025 HPLC-03 Audit Trail Event Log Ajay Verma No abnormal entries

Annexure-3: Data Integrity Incident Register

Incident ID Date Description Action Taken Status
DI/2025/004 10/05/2025 Chromatogram deleted User suspended & retrained Closed

Annexure-4: Data Integrity Training Log

Employee Name Department Training Date Trainer Status
Meenal Patil AMD 01/05/2025 QA Manager Completed

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added annexures for audit trail and training logs GMP Data Review Audit
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: BA-BE Studies: SOP for Reconciliation of Clinical Sample Volumes – V 2.0
Next Post: Creams: SOP for Preservative Efficacy Testing of Creams – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version